Stay updated on SBRT plus Immunotherapy in Early NSCLC Pre-Surgery Clinical Trial

Sign up to get notified when there's something new on the SBRT plus Immunotherapy in Early NSCLC Pre-Surgery Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SBRT plus Immunotherapy in Early NSCLC Pre-Surgery Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, indicating a shift in the number of cycles of immunotherapy (pembrolizumab) received by patients in a study evaluating the safety and mechanisms of action of trimodality treatment for early-stage non-small cell lung cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:55.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the required health conditions and prior treatments for inclusion in the study. This change provides more specific information about the criteria researchers use to select participants for the clinical trial.
    Difference
    42%
    Check dated 2024-05-22T21:02:42.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T21:55:24.000Z thumbnail image

Stay in the know with updates to SBRT plus Immunotherapy in Early NSCLC Pre-Surgery Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SBRT plus Immunotherapy in Early NSCLC Pre-Surgery Clinical Trial page.